Cantor Fitzgerald restated their hold rating on shares of Novavax (NASDAQ:NVAX) in a report released on Tuesday, January 29th. The firm currently has a $2.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Novavax’s FY2019 earnings at ($0.44) EPS.
“: We reaffirm our Neutral rating and $2 PT on NVAX. We believe the company’s portfolio of vaccine candidates has the potential to meaningfully improve the prevention of important infectious diseases. We think the forthcoming release of top-line data from the ResVax Phase 3 trial may be an important catalyst for the stock with the potential to de-risk the company’s most- advanced asset. In our view, understanding the need for and access to additional capital to develop pipeline assets while retaining their potential value is key to evaluating the fair value of the stock.”,” Cantor Fitzgerald’s analyst commented.
Other analysts also recently issued reports about the company. BidaskClub downgraded Novavax from a hold rating to a sell rating in a report on Friday, October 26th. LADENBURG THALM/SH SH initiated coverage on shares of Novavax in a research report on Tuesday, December 18th. They set a buy rating and a $3.00 price target for the company. Oppenheimer initiated coverage on shares of Novavax in a research report on Monday, December 10th. They set an outperform rating and a $4.00 price target for the company. Piper Jaffray Companies upped their price target on shares of Novavax to $4.50 and gave the stock a positive rating in a research report on Thursday, January 3rd. Finally, CIBC initiated coverage on shares of Novavax in a research report on Tuesday, December 11th. They set an outperform rating and a $4.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $4.18.
Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Novavax by 131.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,729 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 9,515 shares during the last quarter. B. Riley Wealth Management Inc. purchased a new position in Novavax in the 3rd quarter valued at about $47,000. Pacer Advisors Inc. purchased a new position in Novavax in the 3rd quarter valued at about $113,000. Cerity Partners LLC boosted its position in Novavax by 51.0% in the 4th quarter. Cerity Partners LLC now owns 63,162 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 21,331 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Novavax by 388.4% in the 2nd quarter. SG Americas Securities LLC now owns 102,003 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 81,117 shares during the last quarter. 40.98% of the stock is owned by institutional investors.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.